Kiwoom Securities forecasted on the 11th that "Quriox Biosystems, the world’s first developer of automated cell analysis equipment, will aim for a performance rebound by launching new equipment at a reasonable price point."
Minsoo Shin, an analyst at Kiwoom Securities, diagnosed that "Quriox Bio’s poor performance last year was due to the high price of fully automated cell analysis equipment and the continued high-interest-rate environment, which prevented multinational pharmaceutical companies from actively allocating budgets for new types of equipment." Quriox Bio recorded sales of 6.8 billion KRW and an operating loss of 10.6 billion KRW last year.
Analyst Shin stated, "To overcome the situation, Quriox Bio plans to release an affordable, entry-level device this summer, priced lower than existing equipment," adding, "They will unveil the Pluto LT, an automated cell analysis device, and the Venus HT, a high-capacity automated cell washing device, to the market."
He noted, "The Pluto LT will enter the market at one-fifth the price of existing equipment," and predicted, "With no disputes over technological capability and the only barrier to sales growth being price now resolved, commercialization will proceed rapidly." He also analyzed, "As the product portfolio diversifies, the customer base will expand as well."
Furthermore, he expressed expectations, saying, "Quriox Bio recently signed a non-exclusive co-selling agreement with Beckman Coulter Life Sciences for cell analysis processes," adding, "This contract opens sales channels and, being non-exclusive, can be presented as a reference when collaborating with other pharmaceutical partners." Beckman Coulter is one of the core subsidiaries of Danaher, which has a market capitalization of $194.9 billion (approximately 274 trillion KRW).
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
